Clinical trial · Interventional
The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies-extension Study
NCT00468260CI-TRIAL-00002790terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): pts. will be captured in core
Summary
Brief summary (as posted)
To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patupilone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Safety
- measure
- Tolerability
- measure
- Potential activity of patupilone once every 21 days in patients that completed the core study
Secondary outcomes (1)
- measure
- Objective response and tumor evaluation assessed by response evaluation criteria in solid tumors (RECIST)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria Participation in study EPO906A2120E1 * Age ≥ 18 years of age * Life expectancy ≥ 3 months * Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist * Completed all PK sampling in the core study Exclusion criteria * Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis * Female patients who are pregnant or breast feeding * Patients with a severe and/or uncontrolled medical disease Other protocol-defined inclusion/exclusion criteria may apply
References
Publications (0)
Data not yet available
No reference posted for this study.